"In addition to the positive results reported last quarter from the investigator initiated phase II study of Trimesta we recently announced that lead investigator Dr. Rhonda Voskuhl of UCLA plans to discuss further findings from this study at the Joint ACTRIMS-ECTRIMS Meeting in September."
"We look forward to updating shareholders on Dr. Voskuhl’s continued analysis as we continue to explore to many different avenues for extracting maximum value for this asset to include finding a potential MS strategic partner."
"A lot of the additional data Dr. Voskuhl will present results from previous and ongoing analysis of patient MRI brain scans. These analysis will continue over the next few months and as you might imagine, as this new outcome data has become available, we've included a new patent filings in ways that we will believe will not only significantly expand and enhance protected features of this increasingly valuable asset, but also substantially lengthen it's market exclusivity."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.